1 / 17

Chris Williams Senior Business Manager Mars Bai Legal Affairs Executive

Chris Williams Senior Business Manager Mars Bai Legal Affairs Executive Biobanks : The role of UCL Business. An Introduction to UCL Business PLC . Most universities have a Technology Transfer office: Imperial Innovations, Cambridge Enterprise, Isis Innovations (Oxford).

gad
Download Presentation

Chris Williams Senior Business Manager Mars Bai Legal Affairs Executive

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chris Williams Senior Business Manager • Mars Bai • Legal Affairs Executive • Biobanks: The role of UCL Business

  2. An Introduction to UCL Business PLC • Most universities have a Technology Transfer office: • Imperial Innovations, Cambridge Enterprise, Isis Innovations (Oxford). • UCLB is a wholly owned subsidiary of UCL: • Our remit is to support the translation and dissemination of UCL research through commercialisation of UCL’s intellectual assets. • Moorfields, GOSH, RFH and UCLH. • UCLB is a commercial entity: • Financially self-sufficient • 55 Employees • Profitable • Strong Board with industry expertise • Part of UCL Enterprise

  3. An Introduction to UCL Business PLC • Our remit is to support the translation and dissemination of UCL research through commercialisation of UCL’s intellectual assets. • Four core business aspects • Service to UCL (and others) • Investment – Licensing • Investment – Company creation • Investment – Product development to market

  4. Biobanks: the role of UCL Business PLC • Our remit is to support the translation and dissemination of UCL research through commercialisation of UCL’s intellectual assets. • Four core business aspects • Service to UCL (and others) MTAs • Investment – Licensing Commercial Access to Material • Investment – Company creation Abcodia Ltd • Investment – Product development to market

  5. Material Transfer Agreements Materials transfer agreements (MTAs) govern the transfer of one or more materials from the owner/custodian/authorised licensee to another entity who may wish to use the material for research purposes.

  6. Why MTAs? • HTA compliance “If human tissue is transferred between establishments given to minimising the likelihood of theft, damage or loss during transport. Some form of formal arrangement, for example, as part of a Material Transfer Agreements (MTA) should define how the human tissue is preserved, any potential contamination risks associated with it and who is responsible for disposal if applicable.” – Section 112, HTA Code of Practice 9 • Liabilities • Publication Acknowledgement • Further information on human tissue transfer: • http://www.ucl.ac.uk/slms/research/human-tissue-act • Further information on MTAs: • http://www.uclb.com/what-we-do/are-you-a-ucl-researcher/material-transfer-agreements

  7. Improve efficiency • Avoid negotiation phase • Automate the application and approval process • Cut out paperwork and physical signatures • Facilitate monitoring and management of agreements • Exportable reporting • Attract interest from external organisations TheRealisationof Research

  8. Biobanks: the role of UCL Business PLC • Our remit is to support the translation and dissemination of UCL research through commercialisation of UCL’s intellectual assets. • Four core business aspects • Service to UCL (and others) MTAs • Investment – Licensing Commercial Access to Material • Investment – Company creation Abcodia Ltd • Investment – Product development to market

  9. Commercial Access to Material • Why do industry want to access biobanks: • Biomarker discovery and validation. • Discovery\validation targets for therapeutic intervention. • Screening therapeutics toxicology\efficacy • Access to the wealth of clinical/experimental expertise at UCL and Partner Hospitals. • Why should we engage with industry: • Collaborative research / commercial impact. • Income generation to maintain the biobank resource. • Income generation to supplement research.

  10. Commercial Access to Material • Important considerations: • Permissions • Grant\funder terms and conditions • Value of samples • Licensing: • Fee for access • Non-exclusive license to material • Value Add

  11. Biobanks: the role of UCL Business PLC • Our remit is to support the translation and dissemination of UCL research through commercialisation of UCL’s intellectual assets. • Four core business aspects • Service to UCL (and others) MTAs • Investment – Licensing Commercial Access to Material • Investment – Company creation Abcodia Ltd • Investment – Product development to market

  12. Company Creation • UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) • Professors Jacobs and Menon UCL IfWH • Incorporated 2010 • Licensed in IPRs and pre-existing license • Secured VC-funding alongside UCLB • Winner of four awards in December 2012 • Exploitation of a unique cohort of longitudinal serum samples for biomarker discovery and validation

  13. Study Overview • Formed from one of the world’s largest cancer screening studies (UKCTOCS) • Funded by MRC, CRUK, NHS. • Collection from >200,000 female volunteers across the UK • Post-menopausal, free from disease at the start of the collection • Repeat samples collected annually from 50,000 volunteers, for up to 10 years • Total of 5 million aliquots of serum, stored sealed straws in liquid nitrogen at -176C • DNA and protein measurable • Associated Clinical Data • Detailed demographic information, including lifestyle data • Emergent disease incidence, plus family disease history • Cancer: Trachea, Bronchus and Lung, Breast, Ovarian, Colorectal, Pancreatic, Bladder and Liver • Non Cancer: Hypertension, diabetes, Angina, Rheumatoid Arthritis, Osteoarthritis, Parkinson’s, Senile dementia. • Ethics and approval • Volunteer consent and ethics approval in place for commercial use

  14. Commercial Opportunities • Uniquely allows within-subject experimental designs • Longitudinal measures of molecular change, ahead of emergent disease • Avoids the need to seek ‘matched’ controls, enables improved measures of sensitivity • Use of the large numbers of subjects remaining disease-free to provide statistical power in cross-subject designs • Biomarker Discovery and Validation • Diagnostics, prognostics or at risk screening • Access for industry at commercial rates. • No cost for academic access.

  15. Any questions? Chris Williams Senior Business Manager Mars Bai Legal Affairs Executive UCL Business PLC The Network Building 97 Tottenham Court Road London W1T 4TP Tel: 020 7679 9000 Web: www.uclb.com Email: m.bai@uclb.com Email: c.williams@uclb.com • Further information on HTA: • http://www.ucl.ac.uk/slms/research/human-tissue-act • Further information on MTAs: • http://www.uclb.com/what-we-do/are-you-a-ucl-researcher/material-transfer-agreements • Further information on UKCTOS: • http://www.instituteforwomenshealth.ucl.ac.uk/academic_research/gynaecologicalcancer/gcrc/ukctocs • Further information on Abcodia: • http://www.abcodia.com/

More Related